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Introduction
For patient's presenting with end-stage chronic liver disease (ESLD) or acute liver failure (ALF), orthotopic transplantation of a donor liver remains the only curative treatment. Due to lengthening waiting lists and a severe scarcity of donors, mortality rates are increasing annually [1] . As a result, an alternative strategy for treating these patients is urgently required. Allogenic transplantation of primary adult hepatocytes, the major functional celltype of the liver, is considered a viable solution in certain clinical indications for example [2] [3] [4] . Lack of sufficient numbers of high-quality hepatocytes; a result of isolating cells from tissue deemed unsuitable for transplantation, has limited the success of this programme [5, 6] . 4 Derivation of human embryonic stem cells (hESCs) [7] and their related induced pluripotent stem cells (hiPSCs) [8, 9] however has generated growing optimism that the development of cellular therapies, such as would be suitable for liver disease, was finally an obtainable goal [10] . Unlike primary hepatocytes, which cannot be cultured or expanded in vitro [11, 12] , human pluripotent stem cells (hPSCs) possess an unlimited ability for self-renewal [13] . This capability to produce large batches of cells is of clinical significance as hepatocytes numbers approaching 8 billion may be required for transplant when correcting metabolic liver function in pediatric patients [14] , or 15 billion to support liver failure in adults [15] . Studies have shown that both hESCs [16, 17] and hiPSCs [18] [19] [20] can be differentiated into hepatocytes (hPSC-Heps), sharing functional attributes of their in vivo equivalents, including albumin / alpha-1 antitrypsin (A1AT) protein secretion, Cytochrome P450 activity and glycogen storage. As research tools, hPSCs have delivered novel insights into human hepatic development [21] , the creation of liver disease models [22, 23] , and provided new platforms for pharmacological testing [24] . Furthermore, the successful, albeit limited, repopulation of rodent livers following transplantation of both hESC, and hiPSC-derived hepatocytes has been reported by several groups [25] [26] [27] , suggesting hPSC-Heps may be a viable treatment option for patients with liver disease.
The stem cell field has developed at an exceptional rate, which has resulted in the first human trials using cells derived from hESCs/hiPSCs being undertaken [28] [29] [30] [31] [32] . While approved for clinical use, these lines were in fact developed for research purposes and not produced under current good manufacturing practice (cGMP) guidelines. These manufacturing regulations for stem cell therapy products are described by the Food and Drug Administration in the United States of America (USA), and since the 2004 European Union Tissues and Cells Directive (EUTCD), the European Medicines Agency within the European Union.
Generating cells under cGMP conditions ensures their clinical safety, and for cellular therapies should be differentiated in fully defined, xeno-free conditions [33] to ensure reproducibility, and prevent xeno-mediated infection or immune rejection [34] .
In 2011 scientists from King's College London submitted the first xeno-free clinical grade hESCs [35] to the UK Stem Cell Bank [36] . More recently, cGMP-compliant hiPSCs have been generated by teams in China [37] , Japan [38] , USA [39] and the United Kingdom [40] .
These clinically compliant lines have been extensively characterized as pluripotent with profiles comparable to previously validated hPSCs derived outside of these manufacturing guidelines [41] . However, given previous reports describing the varied potential for hPSC lines to differentiate into target cell types [42] [43] [44] , evaluation of their hepatic differentiation potential represents an essential pre-requisite to further clinical development work. The objective of this study was therefore to undertake this evaluation and then test the potential of differentiated cells to be engineered into three-dimensional (3D) constructs suitable for clinical application.
Materials & Methods
Cell lines and cell culture Day 21 hPSC-Heps were dissociated into a single-cell suspension using TrypLE Express Enzyme (1X), no phenol red (Thermo Fisher Scientific, Waltham, USA).
Brightfield and immunofluorescence imaging
Brightfield microscopy was performed on a Leica DMIL LED inverted microscope and imaged using the Leica DFC3000 G camera (Leica Microsystems, Wetzlar, Germany).
For immunofluorescence staining, samples were fixed for 10 minutes with 4% w/v PFA, and then blocked and permeabilized in 1% w/v bovine serum albumin (Sigma-Aldrich, St. Louis, USA), 3% donkey serum (Thermo Fisher Scientific, Waltham, USA) and 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, USA). An additional 10 minutes of permeabilization was performed using 0.5% Triton X-100 for detection of nuclear antigens. Primary antibodies were applied for 1 hour and after wash steps Alexa Fluor-555/488 conjugated secondary antibodies (Thermo Fisher Scientific, Waltham, USA) were incubated for 40 minutes. Alginate encapsulation of hPSC-derived hepatocyte spheroids
Encapsulation was performed as previously published [45, 46] . In brief, spheroids were washed in saline before being re-suspended into a final 1.8% ultra-pure low-viscosity, highglucuronic acid (≥60%), sodium alginate (FMC BioPolymer, Drammen, Norway) solution, 
Differentiation of cGMP-compliant stem cells towards hPSC-derived hepatocytes
To prepare for hepatic differentiation, we seeded fragmented hPSC colonies obtained through enzyme-free dissociation with minimal trituration onto gelatin coated tissue culture dishes.
We treated hESCs with the small molecule Y-27632 dihydrochloride, an inhibitor of the RHO/ROCK pathway, overnight to ensure sufficient cell attachment onto the gelatin. We found that the hiPSC lines did not require the addition of this small molecule to be passaged, or adhere to gelatin. We then initiated hepatic differentiation two days post-seeding; having allowed enough time for the hPSCs to reestablish rounded colonies, with the outer cells tending to have a larger, more spread morphology.
We closely monitored the morphology of the cells throughout the differentiation and crosscompared against that of our previous publication, that used non-cGMP-compliant hiPSCs, to ensure appropriate differentiation was achieved (Figure 2A 
Characterization of cGMP-compliant hPSC-derived hepatocytes
We next validated that the cGMP-hPSCs were differentiating through the correct developmental lineage trajectory by collecting the cells and quantifying their mRNA expression at four distinct stages of the protocol ( Figure 3A ). These time-points represent undifferentiated hPSCs, definitive endoderm (DE, day 7), hepatic endoderm (HE, day 14) and finally hPSC-Heps (day 21).
Importantly the expression of NANOG, a key pluripotency gene, is significantly downregulated upon differentiation, and is obsolete at day 21, the stage in which hPSC-Heps have been produced. Furthermore, the expression of both CXCR4 and SOX17, well established markers for both definitive endoderm and primitive endoderm, are found to peak and be significantly upregulated at day 7 of differentiation when compared to undifferentiated hPSCs; after this time-point the expression of both genes dissipates. To assess the correct differentiation into hPSC-Heps, we selected six major hepatic genes for investigation. By day 21 a significant increase in the relative expression of AFP, can be measured. AFP is the gene encoding alpha-fetoprotein, a major plasma protein produced be the developing liver and considered to be the fetal version of albumin [48] . Incidentally, expression of ALB, albeit not significant, is detected at days 14 and 21 of differentiation, with the expression being greatest at the later time-point. This provides evidence that at this stage the cell type produced is one that resembles a maturing hepatocyte. In addition, the relative gene expression for HNF4A, a hepatic transcription factor, as well as ASGR2 (day 21 only), which encodes an asialoglycoprotein receptor isoform primarily found on liver cells, are significantly higher than that of undifferentiated or definitive endoderm cells. In the case of HNF4A, the relative gene expression is peaked at day 14, indicative that the hepatocyte-fate determination has occurred. Moreover, the expression for SERPINF2, the gene encoding the serpin alpha 2-antiplasmin which is secreted in plasma by hepatocytes, is significantly elevated after 21 days of differentiation. Finally, non-significant, but elevated expression of CYP3A7 is detected in day 21 hPSC-Heps than the earlier time-points. This cytochrome P450 3A family isoform is predominately expressed in the developing liver, with the 13 translated enzyme is involved in the metabolism of drugs, together with the synthesis of cholesterol, and various other lipids.
After validating the hepatic specific morphology and gene expression, we next sought to characterize the population profiles of the cells generated using our adapted protocol by performing flow cytometry analysis on day 21 hPSC-Heps ( Figure 3B ). The hepatic progenitor markers EpCAM (98.1%) and cytokeratin-19 (58.8%) were expressed on most cells analyzed. In addition to these hepatic progenitor markers, expression of the asialoglycoprotein receptor 1 (ASGPR1), an endocytotic cell surface receptor specific to adult hepatocytes, was detected on 41.3% of day 21 hPSC-Heps. The presence of hepatocyte progenitor markers and non-significant gene expression of ALB and CYP3A7 displays the need for further maturation culture to produce a cell more closely resembling an adult hepatocyte.
2D maturation of hPSC-Heps
Having validated that cGMP-compliant hPSCs were able to generate cells resembling immature hepatocytes when cultured in our differentiation conditions, we next aimed to advance their hepatic maturation through culturing the cells within different culture model systems to challenge the clinical relevance of our protocols. We first seeded the day 21
hPSC-Heps onto collagen-1 coated tissue culture plastic, as it is an extracellular protein that has been shown capable of supporting the long-term culture, and liver-specific functions, of isolated adult hepatocytes [49] . Upon seeding, the hPSC-Heps recovered their polyhedral morphology within two days. It should be noted that if not seeded to confluency, then many cells do not remain viable in 2D culture on collagen-1, and those remaining do not proliferate, or go on to develop a mature phenotype.
14 After three weeks of maturation culture on collagen-1 coated tissue culture plastic, we performed immunofluorescent staining to assess the hepatic maturity and heterogeneity of the hPSC-Heps ( Figure 4A ). Firstly, none of the pluripotency or endodermal markers, such as OCT4 and CXCR4 are detected in the cultures, which is a good indicator that the conversion of stem cell to hepatic lineage cell was completed in our protocol. It is encouraging to observe hepatocyte-specific markers, for example the nuclear transcription factor, HNF4a
and protease inhibitor, A1AT, to be abundantly expressed throughout the cultures. To further delineate the maturity of hPSC-Heps cultured on collagen-I coated 2D surfaces, we assessed the presence of hepatoblast specification (AFP, KRT19 and EpCAM) and hepatocyte specification (ALB and ASGPR1) markers respectively. We found that even though the expression of mature markers, such as ALB and ASGPR1, are prevalent across the culture, enzyme activity was measurable in the previous assay, the gene expression of CYP3A4 is elevated, but not significantly higher than that of the pre-seeding population. These mRNA expression results corroborate with our immunostaining observation that our cells are yet to achieve advanced maturity in this 2D model system.
To characterize the liver specific functions of the cells, we monitored the albumin production rate ( Figure 4C and Supplementary data 3) and the metabolic activities of the cells over an extended period ( Figure 4D ). As a 2D monolayer, hPSC-Heps secreted albumin at levels detectable by ELISA after 8 days post-seeding. Once cultured for a further week, the amount of albumin protein measured was significantly higher and an indicator of a maturing phenotype. Moreover, the albumin production is comparable between the three lines assessed, with no significant differences measured after 8 or 14 days of maturation.
Furthermore, when cultured for an additional week (21 days post-seeding), non-induced enzyme activity of cytochrome P450 3A4 can be detected ( Figure 4D ). Again, no significant difference between the different cGMP-compliant lines was measured, nor is activity detected in hPSC-Heps after one week of 2D maturation. The presence of CYP3A4 activity, which is initially absent from the liver of new-borns, and responsible for >50% of medicinal drug metabolism, is a clear indicator that the extended culture period results in matured hepatocytes [50, 51] . we have previously demonstrated that human fetal liver-derived organoids can be generated through their culture within this model [52] . To facilitate the characterization of the morphogenic transformation of hPSC-Heps within this scaffold, we performed a series of immunofluorescence staining and constructed the 3D images using confocal microscopy.
Firstly, we observed that upon seeding into the ICC hydrogel, hPSC-Heps establish cellmatrix interactions with the coated ECM protein and achieve confluency over the concave surface of the internal pores of the scaffold within 3-5 days post-seeding ( Figure 5A ). Then by one week, the cells self-assemble into mechanically stable interconnected clusters that Likewise, functional assays for albumin secretion ( Figure 5D ) and CYP3A4 enzyme activity ( Figure 5E ) showed significant improvements for hPSC-Heps matured within the ICC scaffold when compared to their 2D counterparts. The attainment and enhancement of these cellular functions are both major features of advanced hepatic differentiation, and their presence would be an unconditional necessity for any potential stem cell-derived therapy.
Cumulatively, these data confirm that cGMP-compliant hPSC-derived hepatocytes can successfully be matured into a functional hepatic phenotype within a 3D, readily up-scalable, system. This combination of cGMP-compliant cells and a biocompatible scaffold not only provides a platform conducive to the further study of hPSC-Heps, but could also hold potential for future drug development and safety studies, and for assisting as a vehicle for cell transplantation.
Generation of alginate encapsulated hepatocyte spheroids
To assess the broader translational potential of cGMP-compliant hPSC-derived hepatocytes for cell-based therapies aimed at ALF, we carried out microencapsulation of hPSC-Heps within alginate; a methodology that allows transplanted cells to be isolated from the recipient's immune responses [55] . Successful encapsulation of hepatocytes within alginate hydrogels has been reported [56] . However, to reduce the possibility of cell death during the encapsulation process [57] , we utilized an additional established culture model, spheroid culture [58] ; known to both prolong viability [59] and phenotypes of hPSC-Heps [60] (Supplementary data 4).
To generate spheroids for encapsulation ( Figure 6A ), we utilized non-adherent microwell containing plates, called AggreWellä, which have previously been used to generate spheroids from hiPSCs [61] . We centrifuged single cell suspensions of hPSC-Heps into microwells to facilitate cell-cell interactions for spheroid formation in large readily scalable quantities ( Figure 6B ). The spheroids were left in culture for 7 days prior to encapsulation within 1.8% alginate microspheres. The 3D aggregates maintain their structure and uniformity as they are pumped through the microcapsule generator's 0.22mm diameter nozzle at a rate of 10ml/hour. The cross-linking of alginate occurs in under 5 minutes within barium chloride (BaCL), with most microspheres containing a single spheroid. We then washed the collected microspheres in saline and subsequently placed back into HepatoZYME-SFM. To ensure that the viability of these hPSC-Heps was preserved throughout this process, we carried out live/dead immunofluorescence staining using fluorescein diacetate (FDA) and ethidium homodimer-1 (EthD-1) 6 hours after the encapsulation ( Figure 6C ). Confocal microscopy confirmed that both alginate-and non- In summary, we report that a library of cGMP-compliant hPSCs can be differentiated into hepatocytes by a chemically defined protocol, which is suitable for clinical implementation.
We confirm that this development goes via an endoderm-like stage, before immature hepatocytes are obtained after three weeks. When matured by further culture in either 2D, or 3D models, these hPSC-Heps express proteins known to be present on adult hepatocytes, have improved hepatic gene expression, and go on to demonstrate key liver functions.
Discussion
The manufacture of cGMP-compliant hPSC lines and optimization of translationally relevant differentiation technologies, is essential for clinical application of hPSCs [62] . We have, to our knowledge for the first time in this report, validated that a library of clinical grade cGMPhPSC can successfully be differentiated into hepatocytes in a chemically defined protocol.
Cells generated in this way demonstrated genes, proteins and hallmark functional characteristics of hepatocytes, but as shown by us and others previously [63] , fell short of the benchmarks set by primary adult cells. By subsequently seeding these immature hepatocytes into bio-engineered 3D scaffolds fabricated from FDA approved material, we were able to drive the cells into liver tissue functionally approximated to the standard needed for clinical efficacy.
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Following maturation within our 3D scaffold, elevated expression of key hepatic genes, such as ALB, CYP3A7 and CYP3A4 for example were all found to occur. CYP3A7 was first deemed as being exclusively expressed in the developing fetal liver [64] , but it is now known to be present in up to 88% of adult livers [65, 66] . This elevation in expression is of importance because cytochrome P450 enzymes are essential for the metabolism of numerous endogenous compounds and drugs. The CYP3A sub family specifically makes up 30% of the adult liver's cytochrome P450 constituency [67] and metabolize half of marketed drugs [68] .
Importantly, the level of CYP3A4 enzyme activity is also elevated in hPSC-Heps within 3D
ICC culture when compared to 2D; as is the albumin production rate of the cells. It is also important to highlight that this scaffold can be readily scaled-up to hold greater numbers of cells -up to the billions required for human translation -and can be functionalized with different recombinant proteins, molecules or mechanical parameters. Cumulatively, these design features suggest this scaffold could be the ideal carrier for delivering cGMP-compliant hPSC-Heps into human patients.
Assuming delivery of suitable numbers of functionally optimized cGMP cells can be achieved as above, a further challenge for clinical application will be to deal with the potential allogenic immune rejection by the host post engraftment [69] . Alginate hydrogel microencapsulation provides hPSC-derivatives with a physical barrier from the recipient's immune system, through enclosure within a naturally occurring anionic polymer. Alginate, typically obtained from brown seaweed, is considered ideal for biomedical applications due to its biocompatibility, low cost, and ease of gelation [70] . Numerous cell types have successfully been encapsulated within alginate, including mesenchymal stromal cells [71] , pancreatic islets [72] , and human hepatocytes [73] , whilst optimized GMP grade alginate encapsulation protocols have already been established for the transplantation of human hepatocytes to provide metabolic function in patients with ALF [74] . By demonstrating cGMP-derived hepatic constructs remain viable post encapsulation within alginate hydrogel microspheres, we have therefore confirmed a potential road-map of hPSC-hepatocyte production appropriate for human use.
Conclusion
We report here a library of clinical grade hPSCs manufactured under cGMP conditions amenable to reproducible hepatic differentiation, 3D culture and alginate encapsulation that may be suitable for human application. 
